Gilead Sciences announced plans to acquire Arcellx to strengthen its cell therapy portfolio and accelerate the development of innovative treatments for patients with multiple myeloma.
Strategic Acquisition
This acquisition supports the development of anito-cel, an investigational CAR T therapy for multiple myeloma. The collaboration aims to accelerate innovation and expand access to advanced therapies for patients worldwide.
About Anito-cel
Anito-cel is an investigational CAR T-cell therapy designed to target BCMA (B-cell maturation antigen) in patients with relapsed or refractory multiple myeloma. Early clinical data has shown promising response rates and a manageable safety profile.
Strengthening the Portfolio
The acquisition of Arcellx strengthens Gilead's position in the cell therapy space and expands its capabilities in treating hematologic malignancies. This strategic move aligns with Gilead's commitment to developing transformative therapies for patients with serious diseases.
Accelerating Innovation
By combining Arcellx's innovative technology platform with Gilead's extensive resources and expertise in cell therapy manufacturing and commercialization, the companies aim to accelerate the development and delivery of anito-cel to patients in need.
This acquisition represents a significant step forward in expanding treatment options for patients with multiple myeloma and reinforces our commitment to advancing cell therapy innovation.
Global Impact
The collaboration aims to expand access to advanced therapies for patients worldwide, leveraging Gilead's global infrastructure and Arcellx's innovative technology to bring new treatment options to patients with limited alternatives.